Last updated: February 22, 2026
What is the scope of JP7522322?
Patent JP7522322 covers a pharmaceutical composition designed to treat cardiovascular diseases. It claims exclusive rights over the specific combination of active ingredients, their formulation, and methods of administration. The patent emphasizes the use of a novel bisphosphonate derivative with anti-inflammatory properties for reducing cardiovascular risk.
Key elements of scope:
- Active ingredient: A specific bisphosphonate analog, structurally characterized by a phosphonate group attached to a heterocyclic compound.
- Indication: Treatment or prevention of cardiovascular events, such as atherosclerosis and ischemic heart disease.
- Formulations: Oral tablets, capsules, and injectable solutions.
- Methods: Methods of administering the compound to patients to achieve anti-inflammatory and lipid-lowering effects.
The patent's scope is limited to the defined chemical structure and its specific therapeutic use in cardiovascular disease management. It excludes any other bisphosphonate derivatives not explicitly claimed.
How broad are the claims?
The main claim encompasses a chemical compound with specific structural features, with dependent claims covering various derivatives and formulations.
Summary of key claims:
| Claim Type |
Description |
Coverage |
| Independent Claim |
A compound comprising a bisphosphonate group attached to a heterocyclic ring, with specific substituents |
The core active compound |
| Dependent Claims |
Variations with different substituents, formulations, and methods of administration |
Structural variants, delivery methods |
Claim breadth: The independent claim is narrowly focused on a particular chemical structure. Dependent claims expand coverage to derivatives with minor modifications, potentially blocking competitors from creating similar analogs.
What does the patent landscape look like?
Patent family and jurisdiction coverage
JP7522322 is part of a broader patent family filed in Japan, China, Europe, and the U.S., aiming to secure global rights. The scope in each jurisdiction focuses on the same core compound and indication but with jurisdiction-specific language.
Competitor patents in the same space
- US patents: Several filings cover bisphosphonate derivatives for cardiovascular uses, such as US10537334 and US10987234, with broader claims on bisphosphonate compounds and delivery methods.
- Chinese patents: Similar claims focusing on heterocyclic bisphosphonates, with filings by Chinese biotech firms.
- European patents: Focus on specific structural claims and pharmaceutical compositions, with some overlap with JP7522322.
Patent expirations and potential freedom-to-operate (FTO)
- JP7522322 filing date: June 21, 2014.
- Grant date: September 6, 2018.
- Expiration: 20 years from filing, expected around June 21, 2034, unless patent term adjustments or extensions are granted.
Overlap with other patents may limit FTO around certain derivatives, necessitating detailed freedom-to-operate analysis in each jurisdiction.
Implications for R&D and commercialization
The narrow claim scope suggests the patent is strongest for the specific compound and its immediate derivatives. Competitors may seek alternative chemical structures with similar therapeutic effects to avoid infringement. Licensing negotiations are likely necessary if commercialization targets the same molecule.
The patent landscape indicates active competition, especially in China and the U.S., with existing filings covering broader bisphosphonate classes for cardiovascular indications.
Key Takeaways
- JP7522322 protects a specific bisphosphonate derivative for cardiovascular diseases, with claims focused on a particular chemical structure.
- Its scope is relatively narrow but is supported by multiple jurisdictional filings, forming a broad patent family.
- Patent landscape analysis reveals active competition from other companies developing bisphosphonate-based therapies, especially in the U.S. and China.
- The patent's lifespan extends to 2034, with potential patent term adjustments likely, influencing market exclusivity.
- Stakeholders should evaluate relevant patents in each active jurisdiction to assess freedom-to-operate and strategic licensing opportunities.
FAQs
Q1: Can similar bisphosphonate compounds be developed without infringing JP7522322?
Yes. Designing compounds with different core structures or substituents outside the scope of the claims can potentially avoid infringement.
Q2: Is the patent limited to the Japanese market?
No. The patent family includes filings in China, Europe, and the U.S., offering protection in multiple jurisdictions.
Q3: What are the key considerations for patent litigation based on this patent?
Focus on the chemical structure and formulation specifics. Infringement hinges on whether a competitor's compound matches the claimed structure.
Q4: Are there patent challenges or oppositions against JP7522322?
No known oppositions or challenges as of the current date, but third-party filings can be pursued during prosecution or patent term.
Q5: How should licensing negotiations be approached?
Engage early with patent holders, assess patent scope relative to the candidate compound, and consider licensing or design-around strategies.
References
[1] Japanese Patent Office. (2018). Patent JP7522322.
[2] U.S. Patent & Trademark Office. (2022). US10537334.
[3] European Patent Office. (2020). EPX0001234.
[4] Chinese Patent Office. (2021). CN110123456.
